◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound OPTIONAL-ADD LOW

Reishi

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict OPTIONAL-ADD LOW

"Reishi has the best traditional reputation as an evening adaptogen for sleep and stress modulation, but human RCT evidence is mostly limited to fatigue in clinical populations (cancer survivors, neurasthenia). For a healthy 20yo with no chronic disease, the evening sedation effect is real but mild. Look for dual-extract (water + ethanol) products standardized to beta-glucans and triterpenes. Marginal stack item — rotate with chamomile/magnesium for sleep if interested."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★Dylan (20yo MMA athlete + business owner, brain-priority, calm-leaning evening goals, no anticoagulants, athletic-priority)
    OPTIONAL-ADD

    The evening calming effect is real but mild and not differentiated from magnesium glycinate (already V4-locked) or apigenin. The immune-priming benefit is more relevant for cancer survivors or chronic-illness populations than for a healthy young athlete. The anti-platelet effect is a real friction with MMA training — bruising, post-spar bleeding, and any NSAID use for soreness gets harder. Verdict: skip unless Dylan is specifically curious about a 4-week trial of dual-extract reishi for evening calm, in which case 1 g Real Mushrooms PM × 4 weeks, then judge. Quarterly rotation alongside ashwagandha at most. Not a stack staple.

  • ★20-30, brain-priority, sedentary, no contact sport
    OPTIONAL-ADD

    Same logic minus the platelet concern. Worth a 4-8 week trial if interested in mild evening calm and immune support. Stack staple potential for high-stress knowledge workers.

  • 30-50, executive, stress + recovery focus
    OPTIONAL-ADD

    This is closer to reishi's traditional indication — sustained stress, immune support during travel/burnout cycles, evening calm. 1-2 g/day dual extract is reasonable. Rotate with other adaptogens.

  • 50+, mild cognitive decline / mild immune dysfunction
    STRONG CANDIDATE

    Closest to where reishi has the most evidence and traditional use. Immune-priming β-glucans, mild anti-inflammatory triterpenes, evening calm. 1.5-3 g/day. Watch BP and antiplatelet interaction with daily aspirin or DOACs if on them.

  • Anxiety-prone (without other tools yet)
    OPTIONAL-ADD

    Effect is mild and slow. Better tools exist: L-theanine, ashwagandha, magnesium glycinate, lavender oil (Silexan), apigenin, glycine. Reishi is fourth- or fifth-line.

  • Cancer-adjunct (during chemo or radiotherapy, with oncologist)
    CONSIDER

    This is reishi's strongest indication — Jin 2016 Cochrane evidence for tumor response and QoL during conventional treatment. Dose typically 1.8 g 3×/day Ganopoly extract. Must be discussed with oncologist — possible interaction with chemo agents, immunosuppression context.

  • On anticoagulants (warfarin, DOAC, daily aspirin, clopidogrel)
    CAUTION-AVOID

    Bleeding risk from additive antiplatelet effect. If determined to use, requires prescriber clearance and INR monitoring (warfarin).

  • Allergy / atopic / hay-fever-prone
    OPTIONAL-ADD

    Anti-histamine signal is rodent-only (Andoh 2010, PMID 20460776). 1-2 g/day worth trying; quercetin + bromelain or actual cetirizine probably better-evidenced.

  • Combat athletes (MMA / BJJ / boxing / Muay Thai)
    CAUTION-OPTIONAL

    The platelet-aggregation inhibition compounds bruising and post-impact bleeding risk in a sport that already runs high on both. If using, no dose within 1 week of competition, hard sparring days, or weight cut. For most combat athletes the marginal calming benefit isn't worth the friction.

  • Immunosuppressed (transplant, active autoimmune on immunosuppressants, biologics)
    SKIP

    β-glucan immune priming may interfere.

  • Pregnancy / breastfeeding
    SKIP

    No safety data.

▸ Subjective experience (deep)

Onset: 30-90 min for any subjective shift. Most reports describe no acute effect — reishi is felt cumulatively over 2-4 weeks of daily use, not as a discrete dose-by-dose experience like a stimulant or benzodiazepine.

Peak effect (cumulative): 2-4 weeks of daily use. "Calmer baseline, less wired in the evenings, slightly easier sleep onset" is the most common report.

Plateau / character:

  • Mild evening calming — described as "background quieting" rather than sedation. Nothing like the obvious anxiolysis of a benzodiazepine or even kava.
  • Slight "I forgot to feel anxious about that" quality in stress-prone users.
  • Some users report mildly vivid dreams (consistent with serotonergic tone changes if microbiota mechanism is real).
  • Mild fatigue/lethargy at higher doses (3+ g/day) — usually fades within a week or with dose reduction.
  • Very rarely euphoric or stimulating; if you feel "wired", you have a product purity or dose issue.

Taper: Discontinuation is unremarkable for most. No withdrawal syndrome. Rare "I notice my sleep got worse again over a few weeks" after stopping — consistent with weak cumulative tone rather than acute pharmacology.

Honest variability: Roughly 20-30% of users report no perceived effect even at 3 g/day for 8 weeks (consistent with the community repeat-user trend showing 54% neutral). Likely some combination of: (a) product quality — most retail reishi is starch-heavy mycelium-on-grain; (b) microbiota differences — if the mechanism is gut-mediated, baseline microbiome composition matters; (c) responder/non-responder pharmacogenetics — uncharacterized for reishi specifically.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Effectively none documented. Reishi works (when it works) via cumulative tonic effect, not acute receptor occupancy that would deplete or down-regulate.
  • Cycling rationale: Less about tolerance, more about (a) confirming continued benefit vs habit, (b) microbiome resilience, (c) testing whether the perceived effect is real or expectation.
  • Recommended cycle: 6-8 weeks on, 4-6 weeks off. During off-weeks, journal sleep and stress to see if there's a genuine decrement.
  • Reset protocol: No formal washout needed. Simply discontinue.
▸ Stacking deep dive

Synergistic with

  • Cordyceps (231 co-mentions in community data): Most-stacked partner. Cordyceps targets energy/aerobic capacity (CS-4 / militaris improves VO2 indices in small trials), reishi targets calm/immune. No clear pharmacological synergy but symptomatic complementarity. Reasonable mushroom stack: cordyceps AM + reishi PM.
  • Lion's mane (107 co-mentions): Lion's mane covers cognitive support (NGF/BDNF signal — also small evidence base), reishi covers evening calm. Different bioactive classes, no interaction.
  • L-theanine (159 co-mentions): Both mild calming, both gut-microbiome-friendly. No metabolic conflict. Reasonable evening stack at 200 mg theanine + 1 g reishi.
  • Ashwagandha (131 co-mentions): Classic "stress-cycling" stack — both adaptogens, both evening-leaning. Watch for cumulative sedation if dosed close together. Rotate quarterly rather than stack daily.
  • Magnesium glycinate: Neutral co-administration. Both evening, both calming, no PK interaction. Magnesium glycinate is the bigger lever for most users.
  • Omega-3 (124 co-mentions): Neutral. Both anti-inflammatory, no PK conflict.

Avoid stacking with

  • NSAIDs (ibuprofen, naproxen, aspirin daily, ketorolac): Anti-platelet effects stack — bleeding risk during/after hard training sessions or injury management.
  • Warfarin / DOACs (apixaban, rivaroxaban, dabigatran, edoxaban): Bleeding risk. Avoid.
  • Clopidogrel, ticagrelor: Same antiplatelet logic.
  • High-dose fish oil (>3 g/day EPA+DHA): Additive antiplatelet effect at high doses. Modest concern at typical 1-2 g/day omega-3 doses.
  • Immunosuppressants (cyclosporine, tacrolimus, prednisone chronic, methotrexate, biologics): β-glucan immune priming may interfere with intentional immunosuppression. Avoid without prescriber clearance.
  • Strong CYP3A4 inhibitors: Triterpene metabolism partially through CYP3A4; theoretical exposure increase but no documented clinical interaction.

Neutral / safe co-administration

  • Most of Dylan's V4 stack: creatine, magnesium glycinate, NAC, vitamin D3/K2, glycine, citicoline, alpha-GPC, beta-alanine, vitamin C, B-complex — all neutral. No documented interactions.
  • Modafinil — neutral pharmacodynamically (different systems entirely); dopamine.club AI-seeded "caution" entry for adrafinil-reishi is theoretical opposition, not a real clinical signal. Co-administration is fine.
  • Selank, Semax, BPC-157, TB-500 (peptides) — neutral.
  • Caffeine — neutral. Some users prefer to dose reishi PM and caffeine AM, but no PK reason they can't co-exist.
▸ Drug interactions deep dive

Reishi's metabolic and pharmacodynamic profile:

  • β-glucans: Not systemically absorbed → no CYP-mediated drug interaction risk for the polysaccharide arm
  • Triterpenoids: Partial CYP3A4 substrate + weak CYP3A4 inhibitor in-vitro; clinical relevance unclear at supplement doses
  • Antiplatelet activity: Mild but real and additive
  • Mild hypotensive effect: At higher doses (>2 g/day), some users see 3-5 mmHg systolic reduction

Clinically relevant interactions:

1. Anticoagulants / antiplatelets — INCREASED BLEEDING RISK

  • Warfarin, DOACs (apixaban, rivaroxaban, dabigatran, edoxaban), clopidogrel, ticagrelor, prasugrel, daily aspirin (cardio-prophylactic dose 81 mg+): Avoid. Case reports of post-surgical bleeding with reishi + aspirin. The triterpene-mediated platelet aggregation inhibition is mild but real.
  • NSAIDs (ibuprofen, naproxen, ketorolac, diclofenac, indomethacin): Avoid concurrent daily use, especially during injury management with high-dose NSAIDs. PRN single doses of OTC ibuprofen 200-400 mg are likely fine but stop reishi for the duration if NSAIDs are needed >3 days.

2. Antihypertensives — possible additive hypotension

  • ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, diuretics: Possible mild additive effect at >2 g/day reishi. Monitor BP. Not a hard stop.

3. Antidiabetics — possible mild glucose lowering

  • Metformin, sulfonylureas, GLP-1 agonists (semaglutide, retatrutide), SGLT2 inhibitors, insulin: Reishi has mild hypoglycemic effect at supplement doses (Klupp 2015 found this was not clinically meaningful in pooled data, but individual users vary). Monitor glucose if T2D.

4. Immunosuppressants — theoretical antagonism

  • Cyclosporine, tacrolimus, sirolimus, mycophenolate, prednisone (chronic), methotrexate, biologics (TNF inhibitors, JAK inhibitors): The β-glucan immune-priming effect is the theoretical opposite of intentional immunosuppression. Avoid without prescriber clearance.

5. Levothyroxine — possible reduced absorption

  • High polysaccharide load may bind levothyroxine in the gut, similar to fiber supplements. Separate by ≥4 hours.

6. Hepatically metabolized drugs (CYP3A4)

  • Theoretical mild interaction; clinical reports sparse. Statins (atorvastatin, simvastatin), some calcium channel blockers, midazolam, alfentanil, certain SSRIs (sertraline mild), tacrolimus: Watch for unexpected enhanced effect. Not a hard stop, but flag for prescribers.

7. Alcohol — no direct interaction

  • Hepatic load argument is theoretical. Practical reality: Dylan is zero-alcohol baseline; non-issue.

8. Modafinil / armodafinil / adrafinil — no real clinical interaction

  • Dopamine.club's AI-seeded "caution" entries are theoretical pharmacodynamic opposition (stimulant vs calming). At normal doses neither blunts the other; reishi PM + modafinil AM is fine.
▸ Pharmacogenomics

CYP3A4 / 3A5: Triterpene metabolism partially CYP3A4-dependent. CYP3A5 expressers (~10% Caucasians, ~70% Africans) may clear triterpenes faster — possibly explaining some non-responder population. Not characterized in published reishi PK literature.

Dectin-1 (CLEC7A) polymorphisms: Several SNPs (rs2078178, rs16910631, rs3901533) affect β-glucan binding affinity and downstream immune signaling. The Y238X loss-of-function variant (~5-7% of Europeans, heterozygous) is associated with reduced β-glucan response and could theoretically blunt reishi's immune-modulatory benefit. Dylan's 23andMe results (June 2026) will allow inference on this if relevant.

TLR-2 / TLR-4 polymorphisms: Several common variants affect innate immune signaling strength. Less consistently linked to mushroom β-glucan response specifically.

Gut microbiome composition: Probably the biggest pharmacogenomic-equivalent variable. If the sleep/calming pathway is Bifidobacterium-dependent (per Yao 2021), baseline microbiome diversity and Bifidobacterium abundance likely predict who responds and who doesn't. No commercial test currently provides actionable reishi-response prediction.

COMT: Indirect — Met/Met users (slower dopamine clearance, more anxiety-prone) may notice the mild calming effect more than Val/Val. Not specific to reishi.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Real Mushrooms realmushrooms.com / Amazon ~$30/120 caps (500mg, 60 servings) High — Nammex-sourced (Jeff Chilton), fruiting body only, Megazyme β-glucan testing, transparent COA Industry gold standard for fruiting-body-only mushroom extract. Founded by mushroom industry veteran. Verified by independent lab analyses.
Nammex bulk powder nammex.com (B2B) / many retail brands sourced from Nammex varies High Wholesale source for many quality retail brands. If your reishi label says "sourced from Nammex" it's likely real.
Host Defense (Stamets) — fruiting body line hostdefense.com / Amazon ~$35/60 caps Medium-high for fruiting body products; avoid their mycelium-on-grain line (most of their core SKUs) Paul Stamets brand. The fruiting-body line is legitimate; the mainstream "MyCommunity" / mycelium-on-grain SKUs have been criticized by Nammex and independent labs for high starch content.
Mushroom Science mushroomscience.com ~$28/90 caps Medium-high — fruiting-body dual extract, hot-water + ethanol process Smaller niche brand, decent transparency.
Four Sigmatic Reishi foursigmatic.com / Amazon ~$20/20 packets Medium — fruiting body extract but often blended with other ingredients (cocoa, coffee); β-glucan content varies Convenient if you like the delivery format; not the strongest extract per dollar.
Generic Amazon "reishi" capsules various $10-20/60 caps LOW Most are mycelium-on-grain with negligible β-glucan and undetectable triterpenes. Skip.
Whole dried reishi for decoction herb shops, traditional Chinese pharmacies varies Medium — quality varies wildly Traditional decoction (boil 1-2 hr) extracts β-glucans but not triterpenes. Bitter as hell. Authentic but inefficient for modern compliance.

Vendor recommendation for Dylan: Real Mushrooms reishi capsules (https://realmushrooms.com). Fruiting body only, dual extract, third-party tested ≥30% β-glucan, transparent COA on each batch. ~$30 for a 60-day supply at 1 g/day. If trying, this is the minimum quality bar.

Sourcing red flags:

  • "Polysaccharides" without separate β-glucan number on label → likely starch from grain
  • "Mycelium biomass" or "full-spectrum mycelium" as primary ingredient → grain substrate is being counted as active
  • No third-party COA available → don't bother
  • "10:1 extract" with no further detail → marketing weasel
  • Suspiciously cheap ($5-15 for 60 capsules) → almost certainly junk
▸ Biomarkers to track (deep)

Baseline (before starting)

  • Resting HR + BP (3-day morning average) — mild BP-lowering possible at >2 g/day
  • ALT/AST (liver) — covered in Dylan's June 2026 bloodwork
  • CBC + platelet count — covered in June 2026 panel; useful baseline if monitoring antiplatelet effect
  • Fasting glucose + HbA1c — covered in June 2026; modest hypoglycemic effect possible
  • CRP, IL-6 if available — markers of inflammatory tone; reishi may shift these subtly over months
  • Subjective sleep quality VAS (1-10 daily) for 7 days pre-dose
  • Anxiety baseline (GAD-7 or 1-10 daily VAS)
  • Bruising baseline — note current frequency/severity from training. Useful comparator if antiplatelet effect manifests.

During use

  • Weekly: Sleep VAS, anxiety VAS, GI symptoms, bruising/bleeding frequency
  • Weeks 1-2: GI adjustment monitoring (bloating, stool changes)
  • Weeks 1-4: Skin watch — any rash, discontinue
  • Monthly: Morning HR + BP (home cuff is fine)
  • 3 months at >2 g/day: Repeat ALT/AST + CBC if planning long-term use

Post-cycle (after stopping)

  • 2-4 weeks off: Re-evaluate sleep, anxiety, energy baseline to distinguish real effect from habit/placebo
  • Annual repeat bloodwork at any sustained use pattern
▸ Controversies / open debates Live debate

1. "Does reishi actually help sleep in healthy humans?"

  • Animal view: Yes — Yao 2021 (PMID 34211003), Qiu 2021 (PMID 34715778). Sleep latency shortened, sleep time prolonged in mice via gut-microbiota-serotonin axis.
  • Clinical view (humans): No quality RCT in healthy adults. Tang 2005 (PMID 15857210) helped fatigue/well-being in neurasthenia, not pure sleep. Community reports are mild and split.
  • Probable reconciliation: Real effect, small, microbiome-dependent. ~50% of users feel a mild evening calm; ~50% feel nothing. Until there's a healthy-adult RCT this remains "n=1 trial worth doing, low expectations."

2. "Is reishi safe to run year-round?"

  • Optimistic view: Used for 2,000 years in TCM, generally well-tolerated, no convincing chronic toxicity literature.
  • Skeptical view: No long-term (>1 year) prospective safety data in healthy users. The Yuen 2004 (PMID 15464254) hepatotoxicity case is a tail-risk reminder, even if contamination-driven. Antiplatelet effect is real and not always wanted.
  • Practical view: Cycle quarterly. 6-8 weeks on / 4-6 weeks off respects the tonic-rotation tradition and gives a clean way to spot tolerance or low-grade adverse effects.

3. "Mycelium vs fruiting body — does it matter?"

  • Industry / Stamets view: Mycelium has its own bioactives, supplementation is bioactive whether substrate or fruiting body.
  • Nammex / Jeff Chilton view: Mycelium-on-grain products are mostly starch with low β-glucan and undetectable triterpenes; β-glucan-standardized fruiting-body extracts are the only legitimate clinical reishi.
  • Probable answer: Fruiting body is strongly preferred. Mycelium-on-grain products show <2% β-glucan in independent lab tests, vs. fruiting body extracts hitting 20-40%+. The "mycelium has bioactives" claim is true in a petri dish but doesn't survive the dilution by grain substrate.

4. "Does reishi suppress testosterone via 5-α-reductase inhibition?"

  • In-vitro signal: Yes — Liu 2006 (PMID 16962782), IC50 10-100 µM.
  • In-vivo translation: Almost certainly negligible at supplement doses. The 5-α-reductase enzyme is regulated by feedback from circulating DHT, and supplement-dose triterpenes don't reach the µM concentrations in target tissue needed to materially shift the T:DHT ratio.
  • Practical view: Not a meaningful concern for testosterone-conscious athletes. But it's worth noting that the in-vitro pathway exists — if 23andMe shows DHT-pathway concerns (e.g., androgenetic alopecia risk variants) Dylan might find this mildly favorable rather than concerning.

5. "Is the Cochrane cancer review actually positive for reishi?"

  • Headline view: Yes — adjunct reishi improved tumor response and QoL.
  • Cautious view: Jin 2016 (PMID 27045603) flagged "low-to-moderate evidence certainty," small individual trials, mostly Chinese-language sources, no survival benefit. The QoL improvement is the most robust finding.
  • Practical view: For someone in active cancer treatment, the QoL benefit alone is a reasonable case for adjunct use. For a healthy 20yo, the cancer-prevention extrapolation is weak.

6. "How much of the calming effect is placebo?"

  • Skeptic view: Probably most of it in healthy users. The cumulative-over-weeks profile, the lack of acute pharmacology in subjective reports, and the high (54%) neutral response rate in community data all suggest weak true pharmacology + expectation effect.
  • Mechanism view: The gut-microbiota-serotonin axis is real in mice. If it translates even partially to humans, the placebo accusation is overstated.
  • Practical test: Try blinded — if you can't, just self-trial for 4 weeks and judge. Cheap, low risk, marginal expected benefit.
▸ Verdict change log
  • 2026-05-14 — Thorough research-pass complete. Verdict: OPTIONAL-ADD / LOW CONFIDENCE. Best human evidence is cancer-adjunct (Jin 2016 Cochrane, QoL benefit but no survival; PMID 27045603) and clinical neurasthenia (Tang 2005, n=132, 8wk; PMID 15857210). Sleep/calming evidence in healthy adults is rodent-only (Yao 2021 microbiota-serotonin mechanism, PMID 34211003) plus mild positive community signal. CV / metabolic indications negative (Klupp 2015 Cochrane, PMID 25686270). For Dylan: marginal value; mild antiplatelet effect is real friction for MMA training; product purity is the biggest risk variable. Dual-extract fruiting-body only, quarterly rotation if at all.
  • 2026-05-14 — Initial verdict (pre-research-pass): OPTIONAL-ADD / LOW CONFIDENCE. Carried over.
▸ Open questions / gaps Open
  1. Healthy-adult sleep RCT — does the rodent microbiota-serotonin sleep mechanism (Yao 2021) translate to humans at supplement doses? No published trial currently. Strong candidate for future research.
  2. Triterpene oral bioavailability — published rodent BA is 1-5%. Human PK is sparse. Are dual-extract doses actually delivering measurable plasma triterpene? Worth a basic PK study.
  3. Dectin-1 polymorphism response prediction — if responder status really tracks with Dectin-1 SNPs and microbiome composition, a simple screening test could pre-identify non-responders and save healthy users a 4-week trial.
  4. 5-α-reductase activity in humans — Liu 2006 (PMID 16962782) is in-vitro at supraphysiologic concentrations. Does any oral dose produce measurable DHT-suppression in male users? No definitive human study.
  5. Mycelium-on-grain quality crisis — independent lab analyses (Nammex / Open Source Mushrooms 2017-2023) have called out the dominant US retail formulation. Regulatory or label-claim enforcement is essentially nonexistent. Worth tracking as FDA or third-party certification evolves.
  6. Reishi during contact sports — antiplatelet effect + repeated head impact is theoretically a bad combination. No specific safety data. Worth Dylan tracking bruising/bleeding subjectively during any trial.
  7. Long-term (>1 year) safety in healthy users — no prospective cohort data. The traditional view is "completely safe", the data simply doesn't address the question rigorously.

References

Jin X et al. 2016 — Ganoderma lucidum (Reishi mushroom) for cancer treatment, Cochrane systematic review (PMID 27045603)

pubmed.ncbi.nlm.nih.gov · 2016

pooled 5 RCTs (n=373); tumor response 1.5x, QoL benefit, no survival benefit. Best human evidence.

View Study

Klupp NL et al. 2015 — Ganoderma lucidum mushroom for cardiovascular risk factors, Cochrane systematic review (PMID 25686270)

pubmed.ncbi.nlm.nih.gov · 2015

pooled 5 RCTs; no clinically meaningful effect on BP, lipids, glucose, HbA1c in T2D.

View Study

Tang W et al. 2005 — Randomized, double-blind, placebo-controlled study of Ganoderma lucidum polysaccharide extract in neurasthenia (PMID 15857210)

pubmed.ncbi.nlm.nih.gov · 2005

8-week, n=132, Ganopoly 5.4 g/day; significant fatigue + well-being improvement.

View Study

Yao C et al. 2021 — Ganoderma lucidum promotes sleep through gut-microbiota-dependent serotonergic pathway in mice (PMID 34211003)

pubmed.ncbi.nlm.nih.gov · 2021

rodent mechanism for sleep; microbiota-Bifidobacterium-Tph2 axis.

View Study

Qiu Y et al. 2021 — Anti-insomnia mechanism of Ganoderma via central-peripheral multi-level network analysis, BMC Microbiology (PMID 34715778)

pubmed.ncbi.nlm.nih.gov · 2021

34 sedative-hypnotic components, 51 insomnia genes, TNF/CASP3/JUN networks.

View Study

Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. 2011 — Ganoderma lucidum (Lingzhi or Reishi), in Herbal Medicine: Biomolecular and Clinical Aspects (PMID 22593926 / NIH Bookshelf NBK92757)

ncbi.nlm.nih.gov · 2011

standard reference compendium; bioactives, mechanism, traditional use.

View Source

Real Mushrooms — sourcing guide and Nammex-sourced fruiting-body product line

realmushrooms.com

industry-standard transparency on β-glucan testing and fruiting-body-only sourcing.

View Source

Nammex 2017 white paper on the mushroom mycelium-on-grain quality issue

nammex.com · 2017

Jeff Chilton's industry critique; β-glucan vs. starch in retail products.

View Source

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…